Strides Pharma Science is currently trading at Rs. 406.95, up by 8.70 points or 2.18% from its previous closing of Rs. 398.25 on the BSE.
The scrip opened at Rs. 402.00 and has touched a high and low of Rs. 409.65 and Rs. 398.00 respectively. So far 20526 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 550.40 on 22-Jan-2019 and a 52 week low of Rs. 288.00 on 09-Oct-2019.
Last one week high and low of the scrip stood at Rs. 410.10 and Rs. 390.45 respectively. The current market cap of the company is Rs. 3645.25 crore.
The promoters holding in the company stood at 31.28%, while Institutions and Non-Institutions held 46.45% and 22.27% respectively.
Strides Pharma Science has re-launched Ranitidine tablets for the US market. Strides’ Ranitidine Tablets 300 mg (Rx) were within the acceptable limits for NDMA of 96 nanograms per day or 0.32 ppm. The company has now completed comprehensive testing of several of its batches available in market and in stock meeting the limits prescribed by the USFDA. Basis the outcome company has decided to relaunch its product with immediate effect.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
